SELECT PUBLICATIONS

Dang C et al. Preliminary cardiac safety results of dose-dense (DD) doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) with trastuzumab (H) in HER2/ neu overexpressed/amplified breast cancer (BCA). Poster. San Antonio Breast Cancer Symposium 2005;Abstract 2041.

Hudis C et al. Five year follow-up of INT C9741: Dose-dense (DD) chemotherapy (CRx) is safe and effective. San Antonio Breast Cancer Symposium 2005;Abstract 41.

Joensuu H et al; FinHer Study Investigators. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354(8):809-20. Abstract

Piccart-Gebhart MJ et al; Herceptin Adjuvant (HERA) Trial Study Team. Trastuzumab after adjuvant chemotherapy in HER 2-positive breast cancer. N Engl J Med 2005;353(16):1659- 72. Abstract

Press MF et al. Topoisomerase II-alpha gene amplification as a predictor of responsiveness to anthracycline containing chemotherapy in the Cancer International Research Group 006 clinical trial of trastuzumab (herceptin) in the adjuvant setting. San Antonio Breast Cancer Symposium 2005;Abstract 1045.

Romond EH et al. Trastuzumab plus adjuvant chemotherapy for operable HER 2 positive breast cancer. N Engl J Med 2005;353(16):1673-84. Abstract

Slamon D et al. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Presentation. San Antonio Breast Cancer Symposium 2005;Abstract 1.